Clinical Trial Update: Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

This entry notes a phase 1/2 clinical trial evaluating autologous tumor-infiltrating lymphocytes therapy for hepatocellular carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Autologous Tumor-infiltrating Lymphocytes Therapy (tumor-infiltrating lymphocytes (TIL) therapy)

Snippet

Sponsor: Beijing 302 Hospital | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING